Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 FibroGenSeres TherapeuticsPrelude TherapeuticsMacroGenicsMadrigal Pharmaceuticals
SymbolNASDAQ:FGENNASDAQ:MCRBNASDAQ:PRLDNASDAQ:MGNXNASDAQ:MDGL
Price Information
Current Price$19.89$20.16$32.70$30.07$117.02
52 Week RangeHoldBuyHoldBuyBuy
MarketRank™
Overall Score1.81.71.41.41.7
Analysis Score4.13.43.12.43.4
Community Score2.53.01.72.52.8
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.72.5
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$45.83$38.17$54.25$33.30$167.60
% Upside from Price Target130.43% upside89.32% upside65.90% upside10.74% upside43.22% upside
Trade Information
Market Cap$1.82 billion$1.85 billion$1.52 billion$1.80 billion$1.88 billion
Beta1.594.07N/A2.41.19
Average Volume1,420,0291,060,628221,544796,656183,377
Sales & Book Value
Annual Revenue$256.58 million$34.51 millionN/A$64.19 millionN/A
Price / Sales7.1053.48N/A28.09N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$6.14 per share($0.69) per shareN/A$4.71 per share$27.00 per share
Price / Book3.24-29.22N/A6.38N/A
Profitability
Net Income$-76,970,000.00$-70,280,000.00N/A$-151,810,000.00$-83,950,000.00
EPS($0.89)($1.20)N/A($3.16)($5.45)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-191.78%-385.22%N/A-204.31%N/A
Return on Equity (ROE)-48.19%-2,867.98%N/A-65.84%-47.64%
Return on Assets (ROA)-27.72%-51.24%N/A-49.41%-43.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%N/AN/AN/A
Current Ratio6.23%6.73%20.96%6.19%6.84%
Quick Ratio6.13%6.73%20.96%6.19%6.84%
Ownership Information
Institutional Ownership Percentage75.05%94.32%76.21%95.80%74.24%
Insider Ownership Percentage3.39%4.80%N/A9.00%41.89%
Miscellaneous
Employees5991556837029
Shares Outstanding91.56 million91.55 million46.59 million59.97 million16.03 million
Next Earnings Date5/6/2021 (Estimated)5/6/2021 (Estimated)6/15/2021 (Estimated)5/4/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $120.55Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $120.55
americanbankingnews.com - March 24 at 11:54 AM
MDGL Makes Notable Cross Below Critical Moving AverageMDGL Makes Notable Cross Below Critical Moving Average
nasdaq.com - March 23 at 5:42 PM
Madrigal Pharmaceuticals, Inc.(MDGL)Madrigal Pharmaceuticals, Inc.(MDGL)
fool.com - March 11 at 9:27 AM
Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)Leerink Partners Maintains Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
smarteranalyst.com - March 2 at 12:35 PM
Madrigal: 4Q Earnings Snapshot | Raleigh News & ObserverMadrigal: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and HighlightsMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
finance.yahoo.com - February 25 at 7:22 AM
Market insanity hits MicroCapMarket insanity hits MicroCap
fxstreet.com - February 5 at 10:14 AM
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomets Spin-Off, IPO Deluge Hits StreetThe Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
msn.com - February 5 at 10:14 AM
Is MDGL A Good Stock To Buy Now?Is MDGL A Good Stock To Buy Now?
finance.yahoo.com - December 17 at 12:30 AM
Heres Why Were Not Too Worried About Madrigal Pharmaceuticals (NASDAQ:MDGL) Cash Burn SituationHere's Why We're Not Too Worried About Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
finance.yahoo.com - November 24 at 12:09 PM
MDGL Nov 2020 110.000 callMDGL Nov 2020 110.000 call
uk.finance.yahoo.com - November 21 at 8:03 PM
MDGL Nov 2020 80.000 callMDGL Nov 2020 80.000 call
uk.finance.yahoo.com - November 20 at 10:43 PM
MDGL Nov 2020 155.000 callMDGL Nov 2020 155.000 call
uk.finance.yahoo.com - November 20 at 5:41 PM
Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- SlideshowMadrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
seekingalpha.com - November 19 at 8:15 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The ...
apnews.com - November 14 at 1:45 PM
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 TrialMadrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
finance.yahoo.com - November 13 at 10:06 AM
Madrigal completes patient enrollment for late-stage study of experimental NASH treatmentMadrigal completes patient enrollment for late-stage study of experimental NASH treatment
bizjournals.com - November 6 at 2:03 PM
Madrigal: 3Q Earnings SnapshotMadrigal: 3Q Earnings Snapshot
houstonchronicle.com - November 5 at 8:54 AM
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and HighlightsMadrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
finance.yahoo.com - November 5 at 8:54 AM
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American AssociationMadrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association
bloomberg.com - October 3 at 1:30 PM
B.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals IncB.Riley Financial Stick to Their Buy Rating for Madrigal Pharmaceuticals Inc
infosurhoy.com - October 2 at 6:54 PM
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital ...Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital ...
apnews.com - October 1 at 9:34 AM
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 TrialMadrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
marketwatch.com - September 3 at 8:10 AM
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 TrialMadrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
finance.yahoo.com - September 3 at 8:10 AM
DateCompanyBrokerageAction
4/7/2021FibroGenJPMorgan Chase & Co.Upgrade
4/7/2021FibroGenSVB LeerinkLower Price Target
4/7/2021FibroGenRaymond JamesReiterated Rating
4/7/2021FibroGenMizuhoDowngrade
4/7/2021FibroGenHC WainwrightDowngrade
3/31/2021FibroGenBank of AmericaUpgrade
3/8/2021FibroGenJefferies Financial GroupReiterated Rating
5/1/2020FibroGenCowenInitiated Coverage
3/19/2020FibroGenCitigroupLower Price Target
3/11/2021Seres TherapeuticsChardan CapitalUpgrade
3/2/2021Seres TherapeuticsOppenheimerReiterated Rating
12/23/2020Seres TherapeuticsJMP SecuritiesInitiated Coverage
11/23/2020Seres TherapeuticsCanaccord GenuityReiterated Rating
11/9/2020Seres TherapeuticsPiper SandlerBoost Price Target
3/23/2021Prelude TherapeuticsMorgan StanleyBoost Price Target
3/9/2021Prelude TherapeuticsBarclaysInitiated Coverage
10/20/2020Prelude TherapeuticsThe Goldman Sachs GroupInitiated Coverage
6/1/2020MacroGenicsGuggenheimUpgrade
5/29/2020MacroGenicsStifel NicolausBoost Price Target
5/28/2020MacroGenicsBTIG ResearchBoost Price Target
5/17/2020MacroGenicsNomuraReiterated Rating
5/14/2020MacroGenicsWedbushBoost Price Target
5/12/2020MacroGenicsCredit Suisse GroupBoost Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/6/2020Madrigal PharmaceuticalsBMO Capital MarketsBoost Price Target
5/22/2020Madrigal PharmaceuticalsB. RileyBoost Price Target
(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.